| Schedule of Segment Reporting Information, by Segment [Table Text Block] |
| | | Three months ended June 30, | | | Six months ended June 30, | |
| Sale of Product | | 2025 | | | 2024 | | | 2025 | | | 2024 | |
| Theranostics Products | | $ | 1,905,402 | | | $ | 2,169,131 | | | $ | 3,692,456 | | | $ | 4,074,213 | |
| Cobalt Products | | | 678,015 | | | | 592,199 | | | | 750,465 | | | | 826,167 | |
| Nuclear Medicine Standards | | | 1,013,814 | | | | 407,903 | | | | 2,340,580 | | | | 1,173,311 | |
| Medical Device Products | | | 58,089 | | | | — | | | | 110,719 | | | | — | |
| Fluorine Products | | | — | | | | — | | | | — | | | | — | |
| Total Segments | | | 3,655,320 | | | | 3,169,233 | | | | 6,894,220 | | | | 6,073,691 | |
| Corporate revenue | | | — | | | | — | | | | — | | | | — | |
| Total Consolidated | | $ | 3,655,320 | | | $ | 3,169,233 | | | $ | 6,894,220 | | | $ | 6,073,691 | |
| | | Three months ended June 30, | | | Six months ended June 30, | |
| Depreciation and Amortization | | 2025 | | | 2024 | | | 2025 | | | 2024 | |
| Theranostics Products | | $ | 9,895 | | | $ | 5,697 | | | $ | 18,104 | | | $ | 14,743 | |
| Cobalt Products | | | 16,360 | | | | 23,527 | | | | 32,362 | | | | 27,414 | |
| Nuclear Medicine Standards | | | 31,480 | | | | 32,866 | | | | 61,360 | | | | 61,419 | |
| Medical Device Products | | | — | | | | — | | | | — | | | | — | |
| Fluorine Products | | | 26,095 | | | | 26,095 | | | | 52,190 | | | | 57,940 | |
| Total Segments | | | 83,830 | | | | 88,185 | | | | 164,016 | | | | 161,516 | |
| Corporate depreciation and amortization | | | 17,207 | | | | 10,790 | | | | 34,966 | | | | 38,906 | |
| Total Consolidated | | $ | 101,037 | | | $ | 98,975 | | | $ | 198,982 | | | $ | 200,422 | |
| | | Three months ended June 30, | | | Six months ended June 30, | |
| Segment Income (Loss) | | 2025 | | | 2024 | | | 2025 | | | 2024 | |
| Theranostics Products | | $ | 1,009,387 | | | $ | 1,171,390 | | | $ | 1,886,381 | | | $ | 2,184,854 | |
| Cobalt Products | | | (97,040 | ) | | | 99,324 | | | | (245,266 | ) | | | 32,999 | |
| Nuclear Medicine Standards | | | (38,387 | ) | | | (377,758 | ) | | | 229,176 | | | | (368,262 | ) |
| Medical Device Products | | | (201,305 | ) | | | (83,839 | ) | | | (382,974 | ) | | | (112,350 | ) |
| Fluorine Products | | | 3,905 | | | | (26,095 | ) | | | (22,254 | ) | | | (4,846 | ) |
| Total Segments | | | 676,560 | | | | 783,022 | | | | 1,465,063 | | | | 1,732,395 | |
| Corporate loss | | | (837,345 | ) | | | (1,016,467 | ) | | | (1,738,542 | ) | | | (2,119,891 | ) |
| Net Income | | $ | (160,785 | ) | | $ | (233,445 | ) | | $ | (273,479 | ) | | $ | (387,496 | ) |
| | | Three months ended June 30, | | | Six months ended June 30, | |
| Expenditures for Segment Assets | | 2025 | | | 2024 | | | 2025 | | | 2024 | |
| Theranostics Products | | $ | 4,046 | | | $ | — | | | $ | 50,561 | | | $ | 93,924 | |
| Cobalt Products | | | — | | | | 39,799 | | | | 12,835 | | | | 39,799 | |
| Nuclear Medicine Standards | | | 57,449 | | | | — | | | | 75,663 | | | | 49,038 | |
| Medical Device Products | | | — | | | | — | | | | 28,876 | | | | — | |
| Fluorine Products | | | — | | | | — | | | | — | | | | — | |
| Total Segments | | | 61,495 | | | | 39,799 | | | | 167,935 | | | | 182,761 | |
| Corporate purchases | | | — | | | | 4,216 | | | | 22,439 | | | | 32,175 | |
| Total Consolidated | | $ | 61,495 | | | $ | 44,015 | | | $ | 190,374 | | | $ | 214,936 | |
| | | June 30, | | | December 31, | |
| Segment Assets | | 2025 | | | 2024 | |
| Theranostics Products | | $ | 1,358,808 | | | $ | 992,513 | |
| Cobalt Products | | | 122,282 | | | | 167,881 | |
| Nuclear Medicine Standards | | | 2,649,344 | | | | 2,928,814 | |
| Medical Device Products | | | 653,882 | | | | 553,117 | |
| Fluorine Products | | | 4,823,549 | | | | 4,875,738 | |
| Total Segments | | | 9,607,865 | | | | 9,518,063 | |
| Corporate assets | | | 7,902,234 | | | | 7,642,905 | |
| Total Consolidated | | $ | 17,510,099 | | | $ | 17,160,968 | |
|